<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365142</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-PRGF/ART</org_study_id>
    <secondary_id>2011-006036-23</secondary_id>
    <nct_id>NCT02365142</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma</brief_title>
  <acronym>CMM-PRGF/ART</acronym>
  <official_title>Phase I/II. Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma(PRGF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)&#xD;
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet&#xD;
      richa plasma (PRGF) in patients with knee osteoarthritis.&#xD;
&#xD;
      Patients and methods&#xD;
&#xD;
      Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19&#xD;
      patients for each group. The investigators compare the intraarticular injection of against&#xD;
      the administration of two different doses of mesenchymal stem cells with hialuronic acid&#xD;
      according to the following scheme:&#xD;
&#xD;
        1. Group A: 3 intra-articular injections of platelet rich plasma (PRGF®) separated by 7&#xD;
           days.&#xD;
&#xD;
        2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7&#xD;
           days and one with Mesenchimal stems cells. Intra-articular injection of 100 million&#xD;
           autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile&#xD;
           small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by&#xD;
           an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed&#xD;
           with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.&#xD;
&#xD;
      In addition the investigators assess the response to intra-articular infusion of CMM&#xD;
      analyzing the following parameters:&#xD;
&#xD;
        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since&#xD;
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.&#xD;
&#xD;
        -  Radiographic (baseline and 12 months from treatment): Femorotibial space.&#xD;
&#xD;
        -  Radiographic using MRI (baseline and 12 months from treatment): by assessing the number&#xD;
           location of the lesions , cartilage thickness , signal intensity , subchondral bone&#xD;
           alteration , volume and WORMS and dGEMRIC protocols.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: To determine the safety, feasibility and effectiveness (clinical and radiological)&#xD;
      of intra-articular administration of autologous mesenchymal stem cells (MSCs) with platelet&#xD;
      richa plasma (PRGF®) in patients with knee osteoarthritis.&#xD;
&#xD;
      Patients and methods&#xD;
&#xD;
      Clinical trial phase I- II, randomized , multicenter , with two treatment arms and 19&#xD;
      patients for each group. The investigators compare the intraarticular injection of against&#xD;
      the administration of two different doses of mesenchymal stem cells with hialuronic acid&#xD;
      according to the following scheme:&#xD;
&#xD;
        1. Group A: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7&#xD;
           days.&#xD;
&#xD;
        2. Group B: 3 intra-articular injections of platelet richa plasma (PRGF®) separated by 7&#xD;
           days and one with Mesenchimal stem cell. Intra-articular injection of 100 million&#xD;
           autologous mesenchymal progenitor stem cells cultured ex - vivo (cell suspension sterile&#xD;
           small volume (5-10 ml ) in a vehicle suitable for intraarticular injection ) followed by&#xD;
           an intraarticular injection of platelet richa plasma (PRGF®). The treatment is completed&#xD;
           with 2 more injection of platelet richa plasma (PRGF®) separeted by one week.&#xD;
&#xD;
      The autologous mesenchymal stem cells are obtained from the iliac crest under local&#xD;
      anesthesia and sedation. They are cultured ex vivo The primary endpoint is safety and&#xD;
      feasibility. The investigators registered the occurrence of complications and / or adverse&#xD;
      effects during the study.&#xD;
&#xD;
      In addition the investigators assess the response to intra-articular infusion of CMM&#xD;
      analyzing the following parameters:&#xD;
&#xD;
        -  Clinical assessment of pain and function (Baseline, 1, 3, 6 and 12 months since&#xD;
           treatment): VAS , WOMAC , KOOS , EuroQol, SF-16, Lequesne , WOMAC , KOOS.&#xD;
&#xD;
        -  Radiographic (baseline, 6 and 12 months since treatment): Femorotibial space.&#xD;
&#xD;
        -  Radiographic using MRI (baseline, 6 and 12 months since treatment): by assessing the&#xD;
           number location of the lesions , cartilage thickness , signal intensity , subchondral&#xD;
           bone alteration , volume and WORMS and dGEMRIC protocols.&#xD;
&#xD;
      All patients met the following inclusion and exclusion criteria:&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Visual analogue scale (VAS) Baseline Visual analogue scale (VAS)</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline Visual analogue scale (VAS) prior to the initial dose on day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline value of knee injury and osteoarthritis outcome score (Koos).</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention on day 1 value of knee injury and osteoarthritis outcome score (Koos).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).</measure>
    <time_frame>Day 1</time_frame>
    <description>Universities Osteoarthritis Index score (WOMAC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline SF-36 value</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline SF-36 value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline euroquol 5D value</measure>
    <time_frame>Day 1</time_frame>
    <description>Pretreatment euroquol 5D value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lequesne index</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention on day 1 Lequesne index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline femorotibial distance</measure>
    <time_frame>Day 1</time_frame>
    <description>Prior to the intervention femoritibial distance on rosenberg x-ray view</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Follow up (up to 12 months)</time_frame>
    <description>Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events During the follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Visual analogue scale (VAS) at on month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue scale (VAS) at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Visual analogue scale (VAS) at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Visual analogue scale (VAS) at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</measure>
    <time_frame>1 month</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 1 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</measure>
    <time_frame>3 Months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 3 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</measure>
    <time_frame>6 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 6 month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Value of knee injury and osteoarthritis outcome score (Koos) at 12 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>100 million Bone marrow mesenchimal stem cells</intervention_name>
    <description>100 million Bone marrow mesenchimal stem cells with PRGF</description>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich plasma (PRGF)</intervention_name>
    <description>3 injections of PRGF</description>
    <arm_group_label>BMMSC with Platelet Rich Plasma (PRGF)</arm_group_label>
    <arm_group_label>Platelet Rich Plasma (PRGF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 40 and 80 year old&#xD;
&#xD;
          -  Bad results with previous hyaluronic acid injection&#xD;
&#xD;
          -  Diagnosis of knee OA according to the criteria of osteoarthritis of the ACR (American&#xD;
             College of Rheumatology)&#xD;
&#xD;
          -  Joint pain equal or greater than 2.5 points on the visual analogue scale (VAS)&#xD;
&#xD;
          -  Radiological Classification: Kellgren-Lawrence scale greater or equal to 2&#xD;
&#xD;
          -  Body mass index between 20 and 35 kg/m2&#xD;
&#xD;
          -  Ability to follow during the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral Osteoarthritis of the Knee requiring treatment in both knees&#xD;
&#xD;
          -  Previous diagnosis of polyarticular disease&#xD;
&#xD;
          -  Severe mechanical deformation&#xD;
&#xD;
          -  Arthroscopy during the previous 6 months&#xD;
&#xD;
          -  Intraarticular infiltration of hyaluronic acid in the last 6 months&#xD;
&#xD;
          -  Systemic autoimmune rheumatic disease&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus&#xD;
&#xD;
          -  Blood dyscrasias&#xD;
&#xD;
          -  Immunosuppressive or anticoagulant treatments&#xD;
&#xD;
          -  Treatment with corticosteroids in the 3 months prior to inclusion in the study&#xD;
&#xD;
          -  NSAID therapy within 15 days prior to inclusion in the study&#xD;
&#xD;
          -  Patients with a history of allergy to penicillin or streptomycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Lamo-Espinosa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felipe Prosper, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clínica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Blanco, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Universitario de Salamanca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla-León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departamento Cirugía Ortopédica y Traumatología. Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es/actualidad/noticias/celulas-madre-osea-artrosis-rodilla</url>
    <description>University clinic of navarre trial information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Mesenchimal stem cell</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

